Merck News (NYSE:MRK)

DateTimeSource
Headline
09/23/20169:41AMDJNMerck's Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
BEIJING -- Merck & Co.'s immunotherapy cancer drug Keytruda is finding its way into China as the first imported drug approved for use under a pilot program on the resort island of Hainan intended to boost medical tourism. The fast-track entry for Keytruda into China, albeit limited, is likely to give Merck an... More...>>
09/23/20168:00AMBWMerck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 25. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
09/20/20168:30AMBWMerck to Host Investor Teleconference to Discuss ESMO 2016 Highlights
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. The call will take place on Sunday, Oct. 9 at 6:30 p.m. CEST (12:30 p.m... More...>>
09/20/20163:03AMDJNBusiness Watch -- WSJ
KMART Chain to Close More Locations Kmart is closing an additional 64 locations, according to a person familiar with the matter, as the struggling department-store chain continues to shrink its footprint. The latest closures, which were announced to employees, are in addition to a decision in April by parent Sears Holdings... More...>>
09/19/201611:49AMDJNSanofi Files Suit Against Merck, Claiming Patent Infringements -Update
By Noemie Bisserbe and Inti Landauro PARIS-- Sanofi SA said it filed a lawsuit against Merck & Co. for alleged patent infringements to prevent the U.S. drugmaker from launching a rival version of the French pharmaceutical giant's best-selling diabetes treatment Lantus. In the filing in the U.S. District Court... More...>>
09/19/20168:30AMDJNSanofi Files Suit Against Merck
PARIS—Sanofi SA said it filed a lawsuit against Merck & Co. for alleged patent infringements to prevent the U.S. drugmaker from launching a rival version of the French pharmaceutical giant's best-selling diabetes treatment Lantus. In the filing in the U.S. District Court of Delaware, Sanofi said on Monday... More...>>
09/19/20168:14AMDJNSanofi Files Suit Against Merck on Patent Infringements -Update
By Noemie Bisserbe and Inti Landauro PARIS-- Sanofi SA said it filed a lawsuit against Merck & Co. for alleged patent infringements to prevent the U.S. drugmaker from launching a rival version of the French pharmaceutical giant's best-selling diabetes treatment Lantus. In the filing in the U.S. District Court... More...>>
09/19/20162:08AMDJNSanofi Files U.S. Suit Against Merck on Patent Infringements
By Inti Landauro PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) Monday said it filed a lawsuit against Merck & Co.'s international unit for alleged patent infringements. In the filing in the U.S. district court of Delaware, Sanofi said it claims that Merck Sharp & Dohme Corp. violated as many as 10... More...>>
09/15/201610:03AMDJNMerck, Pfizer Diabetes Therapy Meets Late-Stage Study Goals
By Tess Stynes Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said their investigational diabetes treatment helped lower blood-glucose levels in patients with hard-to-treat cases of type 2 diabetes, meeting the main targets in a late-stage clinical study. The phase 3 study data was presented at an industry conference... More...>>
09/13/201610:30PMDJNObama Administration Makes Last-Ditch Push for Trade Vote
The Obama administration is enlisting business leaders in a last-ditch effort to win Republican support for its signature Pacific trade agreement after the election. A business-led advisory committee known as the President's Export Council is expected Wednesday to call on Congress to pass the Trans-Pacific Partnership... More...>>
09/13/20169:00AMBWMerck Publishes 2015/2016 Global Corporate Responsibility Report
Report Highlights Company’s Long-Standing Commitment to Discovering Innovative and Sustainable Solutions to the World’s Greatest Health and Development Challenges Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2015/2016 global corporate responsibility report. The report reflects... More...>>
09/13/20163:15AMPRNCAMerck's Consumer Health Business Presents New Purpose to Help Prepare Society for 100 Healthy Years
Merck's Consumer Health Business Presents New Purpose to Help Prepare Society for 100 Healthy Years Canada NewsWire DARMSTADT, Germany, Sept. 13, 2016 DARMSTADT, Germany, Sept. 13, 2016 /CNW/ - "WE100" movement will promote activities to prepare society for 100 healthy years across generations Merck, a leading... More...>>
09/12/20168:00AMPRNCANew Biosimilar can Offer an Effective and Lower Cost Treatment Option for Canadians Living with Rheumatoid Arthritis and Anky...
New Biosimilar can Offer an Effective and Lower Cost Treatment Option for Canadians Living with Rheumatoid Arthritis and Ankylosing Spondylitis Canada NewsWire KIRKLAND, QC, Sept. 12, 2016 BRENZYS™ is the first subcutaneous anti-TNF biosimilar medicine approved in Canada Biosimilars can provide a lower-cost option for... More...>>
09/12/20168:00AMPRNCAUn nouveau produit biosimilaire peut offrir une option thérapeutique efficace et à moindre coût pour les Canadiens souffra...
Un nouveau produit biosimilaire peut offrir une option thérapeutique efficace et à moindre coût pour les Canadiens souffrant de polyarthrite rhumatoïde et de spondylarthrite ankylosante Canada NewsWire KIRKLAND, QC, le 12 sept. 2016 BRENZYSMC est le premier médicament biosimilaire anti-TNF sous-cutané... More...>>
09/09/20168:00AMBWMerck to Participate at the Morgan Stanley Global Healthcare Conference
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 12... More...>>
09/08/20163:04AMDJNBusiness Watch -- WSJ
MERCK FDA to Review Immunotherapy Drug The U.S. Food and Drug Administration will review Merck & Co.'s immunotherapy cancer drug Keytruda as a first-line treatment for patients with the most common form of lung cancer, the company said Wednesday. The FDA granted Keytruda, or pembrolizumab, breakthrough therapy... More...>>
09/07/20162:42PMDJNFDA to Review Merck Drug as First-Line Treatment for Lung Cancer
The U.S. Food and Drug Administration will review Merck & Co.'s immunotherapy cancer drug Keytruda as a first-line treatment for patients with the most common form of lung cancer, the company said Wednesday. The FDA granted Keytruda, or pembrolizumab, breakthrough therapy designation and priority-review status... More...>>
09/07/20168:50AMDJNFDA to Review Merck's Keytruda as First-Line Treatment for Lung Cancer
By Anne Steele The U.S. Food and Drug Administration will review Merck & Co.'s immunotherapy cancer drug Keytruda as a first-line treatment for patients with the most common form of lung cancer, the company said Wednesday. The FDA granted Keytruda, or pembrolizumab, breakthrough therapy designation and priority-review... More...>>
09/07/20166:45AMBWFDA Accepts Supplemental Biologics License Application, Assigns Priority Review & Grants Breakthrough Therapy Designation to ...
Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1... More...>>
09/02/20169:42AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to trade actively in Friday's session are Merck & Co. (MRK), Ambarella Inc.(AMBA) and Broadcom Ltd. (AVGO). Merck & Co. said it would discontinue developing the osteoporosis drug odanacatib and not seek regulatory approval for the treatment because of the higher risk... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20160926 07:05:11